UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  April 29, 2011

 

Abbott Laboratories

(Exact name of registrant as specified in its charter)

 

Illinois

 

1-2189

 

36-0698440

(State or Other Jurisdiction of
Incorporation)

 

(Commission File Number)

 

(IRS Employer Identification
No.)

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (847) 937-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07   Submission of Matters to a Vote of Security Holders.

 

Abbott Laboratories held its Annual Meeting of Shareholders on April 29, 2011.  The following is a summary of the matters voted on at that meeting.

 

(a)          The shareholders elected Abbott’s entire Board of Directors.  The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number of shares withheld, and broker non-votes, with respect to each of these persons, were as follows:

 

Name

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

 

Robert J. Alpern, M.D.

 

1,097,053,187

 

6,324,721

 

216,314,532

 

Roxanne S. Austin

 

1,091,618,202

 

11,759,707

 

216,314,532

 

W. James Farrell

 

1,063,585,536

 

39,792,373

 

216,314,532

 

H. Laurance Fuller

 

1,059,423,868

 

43,954,041

 

216,314,532

 

Edward M. Liddy

 

1,067,262,572

 

36,115,337

 

216,314,532

 

Phebe N. Novakovic

 

1,096,524,391

 

6,853,518

 

216,314,532

 

William A. Osborn

 

1,065,086,057

 

38,291,851

 

216,314,532

 

Samuel C. Scott III

 

1,095,726,336

 

7,651,573

 

216,314,532

 

Glenn F. Tilton

 

1,093,943,064

 

9,434,845

 

216,314,532

 

Miles D. White

 

1,059,296,381

 

44,081,528

 

216,314,532

 

 

(b)         The shareholders ratified the appointment of Deloitte & Touche LLP as Abbott’s auditors.  The number of shares cast in favor of the ratification of Deloitte & Touche LLP, the number against, the number abstaining, and broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

1,307,882,710

 

8,780,993

 

3,028,738

 

0

 

 

2



 

(c)          The shareholders voted to approve the compensation of Abbott’s named executive officers listed in the proxy statement for the 2011 annual meeting.  The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

856,801,936

 

239,290,915

 

7,285,058

 

216,314,532

 

 

(d)         The shareholders voted to approve management’s recommendation that Abbott present shareholders with the opportunity to vote on the compensation awarded to its named executive officers annually.  The shareholder vote is advisory and non-binding.  The number of shares cast in favor of holding the vote annually, every two years or every three years, the number abstaining and the number of broker non-votes were as follows:

 

Annual

 

Every Two Years

 

Every Three Years

 

Abstain

 

Broker Non-Votes

 

986,335,153

 

9,417,905

 

101,442,161

 

6,182,690

 

216,314,532

 

 

(e)          The shareholders rejected a shareholder proposal requesting Abbott’s Board of Directors to create and implement a policy of price restraint on branded pharmaceuticals. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

28,195,661

 

914,726,421

 

160,455,827

 

216,314,532

 

 

3



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ABBOTT LABORATORIES

 

 

 

 

Date: May 5, 2011

By:

/s/ Thomas C. Freyman

 

 

Thomas C. Freyman

 

 

Executive Vice President, Finance

 

 

and Chief Financial Officer

 

4